Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse
Nicholas van As(Institute of Cancer Research), Robert Huddart(Institute of Cancer Research), David Bloomfield(Royal Sussex County Hospital), Julian Money‐Kyrle(Royal Surrey County Hospital), Duncan C. Gilbert(Royal Sussex County Hospital), A. Horwich(Institute of Cancer Research), D.P. Dearnaley(Royal Marsden NHS Foundation Trust), S. Beesley(Maidstone Hospital)
Cited by 94
Related Papers
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20
|European Journal of Cancer|2005|576
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
|Journal of Clinical Oncology|2003|548
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|280